Bender Robert & Associates Acquires New Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Bender Robert & Associates acquired a new stake in Chimerix, Inc. (NASDAQ:CMRX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 10,609 shares of the biopharmaceutical company’s stock, valued at approximately $37,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CMRX. Peapod Lane Capital LLC purchased a new stake in Chimerix in the 4th quarter valued at about $2,626,000. Assenagon Asset Management S.A. raised its holdings in Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after buying an additional 496,823 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after buying an additional 138,098 shares during the period. Valeo Financial Advisors LLC raised its holdings in Chimerix by 78.8% in the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after buying an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC purchased a new stake in Chimerix during the fourth quarter worth about $221,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Stock Performance

Shares of Chimerix stock opened at $8.45 on Wednesday. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.47. The company has a market cap of $759.96 million, a PE ratio of -8.99 and a beta of 0.32. The business has a 50-day simple moving average of $4.54 and a 200-day simple moving average of $2.43.

Analyst Ratings Changes

A number of brokerages have issued reports on CMRX. Wedbush reiterated a “neutral” rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Insider Transactions at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by corporate insiders.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.